Sarepta announced positive 12week expression and safety results for SRP9001103 the first results from a clinical trial using SRP9001 commercially representative material In May 2021 the Company announced results from the first 11 participants enrolled in Study SRP9001103 an openlabel study known as ENDEAVOR being conducted in partnership with Roche